The Center for Research in Inflammatory Diseases (CRID) was created with the aim of producing integrative and translational scientific research to identify and validate new biological pathways involved in the induction and resolution of inflammation. To this end, it counts on the experience of researchers from various fields of Biomedical Sciences linked to basic research (genetics, molecular and cell biology, immunology, pharmacology, and pathology) and clinical research (rheumatology, immunology, infectology, and dermatology), in addition to researchers in the area of bioinformatics.
Inflammatory diseases constitute a complex and heterogeneous group of diseases that affect more than 10% of the world population. The treatment alternatives currently available are limited and, in some cases, ineffective, considering that information on the underlying mechanisms of the inflammatory process and the pathophysiology of inflammatory diseases is still lacking.
The specific objective of the Center is to advance knowledge about inflammatory diseases (infectious, autoimmune, and related to the cardiovascular system) to recognize and understand the molecular, immunological, pathological, and pharmacological mechanisms involved; identify new biological targets for the development of pharmacological therapeutic tools; search for possible diagnostic markers and prognostic indications, and apply new knowledge to design and synthesize molecules aimed at treating inflammatory diseases.
The discovery is reported by researchers at Harvard University and the University of São Paulo in Nature Neuroscience, and could serve as a basis for the development of treatments for different diseases.
In a study conducted by researchers at the University of São Paulo involving experiments on mice, the synthetic substance not only prevented the neuropathic pain typically induced by chemo drugs but was also beneficial against cancer.
Researchers affiliated with a FAPESP-funded research center showed that a protein called gasdermin D is involved in septic patients’ organ lesions. The study also proved that a drug originally indicated to treat alcohol dependence can inhibit the molecule’s action and prevent complications.
Many patients suffer from a significant decline in immunity lasting for years after they are discharged from hospital. In an article published in the journal Immunity, Brazilian researchers reveal why this happens.
A group at the University of Campinas used protein mapping to show how abnormal levels of the neurotransmitter glutamate impair the functioning of neurons and oligodendrocytes. The findings could serve as a basis for more effective treatment.
A study by the University of São Paulo has discovered that when macrophages engulf cells infected by the novel coronavirus, they begin producing excessive amounts of pro-inflammatory molecules, and their capacity to recognize and phagocytize dead cells is reduced twelvefold.
In a study of the effects of cigarette smoking on exacerbation of the disease, scientists at a FAPESP-supported research center identified a novel pathway in the inflammatory process relating to bone damage.